BMO Capital analyst Jeffrey Silber maintains Stride (NYSE:LRN) with a Outperform and raises the price target from $47 to $48.
Oppenheimer Maintains Outperform on Blueprint Medicines, Raises Price Target to $90
Oppenheimer analyst Matthew Biegler maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $80 to $90.
